CCP
ALDR

Clough Capital Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

Clough Capital Partners’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-468,435
Closed -$9.74M – 190
2016
Q4 		$9.74M Buy
468,435
+294,035
+169% +$7.65M 0.65% 51
2016
Q3 		$5.71M Buy
174,400
+146,000
+514% +$4.45M 0.3% 92
2016
Q2 		$709K Buy
+28,400
New +$768K 0.04% 147

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Clough Capital Partners's ALDR Position: Q1 2017 in Review

Clough Capital Partners sold out of Alder Biopharmaceuticals (ALDR) in Q1 2017, closing a stake of 468,435 shares — an estimated $9.74M sold.

Clough Capital Partners first reported a position in ALDR in Q2 2016 and held it in 3 quarters. The position peaked at $9.74M in Q4 2016. 142 funds tracked by Wall St. Rank hold ALDR as of Q1 2017.

  • Clough Capital Partners reported no remaining Alder Biopharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Clough Capital Partners sold 468,435 Alder Biopharmaceuticals shares in Q1 2017, an estimated $9.74M.
  • Clough Capital Partners first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Clough Capital Partners's Alder Biopharmaceuticals position peaked at $9.74M in Q4 2016.
  • 142 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2017.

Based on Clough Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.